Understanding and Mitigating Endpoint Bias in External Control Arms
from The Effective Statistician - in association with PSI Hosted by Alexander Schacht and Benjamin Piske, biometricians, statisticians and leaders in the pharma industry
External control arms are becoming increasingly important in drug development, but creating valid comparisons requires more than matching patient populations. In this episode, I speak with Ben Ackerman, Director of Real-World Biostatistics at GSK, about one of the most overlooked challenges in external control arm studies: endpoint bias. We discuss why differences in how outcomes are measured can influence study results, what researchers should consider when designing studies, and how the field is evolving to address these challenges. If you work with real-world evidence, causal inference, or innovative clinical trial designs, this episode offers valuable insights into improving the credibility and transparency of external control arm analyses.
Embed this episode
No transcript yet.